



## Datasheet for ABIN2785690 anti-GALE antibody (N-Term)



[Go to Product page](#)

### 1 Image

#### Overview

Quantity:	100 µL
Target:	GALE
Binding Specificity:	N-Term
Reactivity:	Human, Mouse, Rat, Dog, Pig, Rabbit, Cow, Guinea Pig
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This GALE antibody is un-conjugated
Application:	Western Blotting (WB)

#### Product Details

Immunogen:	The immunogen is a synthetic peptide directed towards the N terminal region of human GALE
Sequence:	AEKVLVTGGA GYIGSHTVLE LLEAGYLPVW IDNFHNAFRG GGSLPESLRR
Predicted Reactivity:	Cow: 93%, Dog: 86%, Guinea Pig: 86%, Human: 100%, Mouse: 91%, Pig: 91%, Rabbit: 92%, Rat: 91%
Characteristics:	This is a rabbit polyclonal antibody against GALE. It was validated on Western Blot using a cell lysate as a positive control.
Purification:	Affinity Purified

#### Target Details

Target:	GALE
---------	------

## Target Details

---

Alternative Name: [GALE \(GALE Products\)](#)

---

Background: GALE is an UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified.

Alias Symbols: SDR1E1

Protein Interaction Partner: GALE, SUMO2, UBC, BAG3, FN1, APP,

Protein Size: 348

---

Molecular Weight: 38 kDa

---

Gene ID: 2582

---

NCBI Accession: [NM\\_001008216](#), [NP\\_001008217](#)

---

UniProt: [Q14376](#)

---

Pathways: [Response to Water Deprivation](#), [Cellular Glucan Metabolic Process](#)

---

## Application Details

---

Application Notes: Optimal working dilutions should be determined experimentally by the investigator.

---

Comment: Antigen size: 348 AA

---


Restrictions: For Research Use only

---

## Handling

Format:	Liquid
Concentration:	Lot specific
Buffer:	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice:	Avoid repeated freeze-thaw cycles.
Storage:	-20 °C
Storage Comment:	For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

## Images



### Western Blotting

**Image 1. WB Suggested Anti-GALE Antibody Titration:** 0.2-

1 ug/ml

**ELISA Titer:** 1:312500

**Positive Control:** Human Liver